SHORT PROPOSAL “CLINICAL RESEARCH GROUPS”

*Version 16.09.2022*

GENERAL INFORMATION

Table 1: Key data of the Clinical Research Group

|  |  |
| --- | --- |
| **Full title of the Clinical Research Group** |  |
| **Short title of the Clinical Research Group** | *Acronym* |
| **Lead Institution** |  |
| Field of science and technology classification[[1]](#footnote-1) |  |
| Address |  |
| Costs | Total costs in Euro (incl. in-kind contributions):Total requested funding in Euro: |
| Start date |  |
| Goals | *Please present the goals and innovative contents of the Clinical Research Group using a maximum of 5 sentences.* |

Table 2: Key data of the Mentor

|  |  |
| --- | --- |
| **Mentor** |  |
| Organisation |  |
| Department/Institute |  |
| Field of science and technology classification1 |  |
| Position in Lead Institution |  |
| Email |  |
| Telephone |  |
| ORCID |  |

Table 3: Key data of the Head

|  |  |
| --- | --- |
| **Head** |  |
| Organisation |  |
| Department/Institute |  |
| Field of science and technology classification1 |  |
| Position in Lead Institution |  |
| Email |  |
| Telephone |  |
| ORCID |  |

Table 4: Key data of Work Package/Sub-Project Leader 1 (Deputy Head)

|  |  |
| --- | --- |
| **Work Package/Sub-Project Leader 1 (Deputy Head)** |  |
| Organisation |  |
| Department/Institute |  |
| Field of science and technology classification1 |  |
| Position |  |
| Email |  |
| Telephone |  |
| ORCID |  |

*(Please multiply the table below as needed)*

Table 5: Key data of Work Package/Sub-Project Leader 2

|  |  |
| --- | --- |
| **Work Package/Sub-Project Leader 2** |  |
| Organisation |  |
| Department/Institute |  |
| Field of science and technology classification1 |  |
| Position |  |
| Email |  |
| Telephone |  |
| ORCID |  |

Cooperation Partner(s):

*(Please multiply the table below as needed)*

Table 6: Key details of Cooperation Partner 1

|  |  |
| --- | --- |
| **Cooperation Partner 1** |  |
| Department/Institute |  |
| Field of science and technology classification1 |  |
| Contact person |  |
| Email |  |
| Telephone |  |

CONTENTS

[List of figures 4](#_Toc114225301)

[List of tables 4](#_Toc114225302)

[1. Abstract (approx. half a page/1500 characters) 5](#_Toc114225303)

[2. Short CRG description (5 to max. 10 pages) 5](#_Toc114225304)

[2.1. Introduction, background and state of the art (max. 2500 characters) 5](#_Toc114225305)

[2.2. Objectives, hypotheses and research questions (max. 2000 characters) 5](#_Toc114225306)

[2.3. Overview of the planned research design (general overview of plans for 8 years, a more detailed overview for the first 4 years) (max. 2000 characters) 5](#_Toc114225307)

[2.4. Scientific methods, study design and research design (including work packages/sub-projects) and feasibility (max. 2000 characters) 5](#_Toc114225308)

[2.5. Expected results, clinical relevance/impact and novelty (level of innovation) 6](#_Toc114225309)

[2.6. Schedule/research project overview 7](#_Toc114225310)

[2.7. Interdisciplinary collaborative aspects, role of team members/researchers (max. 1500 characters) 8](#_Toc114225311)

[2.8. Measures to advance research careers and description of the role of the Mentor (max. 1500 characters) 8](#_Toc114225312)

[2.9. Potential ethical aspects (max. 700 characters) 8](#_Toc114225313)

[3. Financial plan 9](#_Toc114225314)

[4. Authorisation and Affirmation 10](#_Toc114225315)

[5. Attachments 11](#_Toc114225316)

# List of figures

[Figure 1: Gantt chart of the research project 7](#_Toc114225259)

# List of tables

[Table 1: Key data of the Clinical Research Group 1](#_Toc114225291)

[Table 2: Key data of the Mentor 1](#_Toc114225292)

[Table 3: Key data of the Head 2](#_Toc114225293)

[Table 4: Key data of Work Package/Sub-Project Leader 1 (Deputy Head) 2](#_Toc114225294)

[Table 5: Key data of Work Package/Sub-Project Leader 2 2](#_Toc114225295)

[Table 6: Key details of Cooperation Partner 1 3](#_Toc114225296)

[Table 7: Work packages/sub-projects and their expected results 6](#_Toc114225297)

[Table 8: Financial plan of Funding Period 1 9](#_Toc114225298)

[Table 9: Authorisation and affirmation of institutions and key personnel 10](#_Toc114225299)

**SHORT PROPOSAL**

Abstract (approx. half a page/1500 characters)

*Please note: The international experts for the evaluation of your proposal are selected based on your statements in the abstract.*

*The concise summary must include the following points:*

* *Initial situation, problem to solve, and motivation to carry out the clinical research group.*
* *Goals and level of innovation compared to the state of the art (level of technology/knowledge).*
* *Expected results and findings.*

Short CRG description (5 to max. 10 pages)

* 1. Introduction, background and state of the art (max. 2500 characters)

*Describe the current state of the art, i.e. current level of technology/knowledge relevant to the research project, based on the following criteria:*

* *State of the art – current level of technology/knowledge in the research institution itself, in the national innovation system in Europe (including EU projects) and internationally.*
* *Relevant procedures or services that already exist.*
* *Relevant alternative methods and approaches that might be in competition with the proposed approach.*
	1. Objectives, hypotheses and research questions (max. 2000 characters)
* *Give a concise description of the CRG’s research project and scientific objectives.*
* *Outline the research questions, hypotheses, and the scientific challenges the CRG addresses.*
* *Describe the different work-packages/sub-projects and objectives.*
* *All individual work packages/sub-projects must be part of the larger research project, and in combination create benefit.*
* *The objectives should be achievable within the duration of your CRG. Clearly describe the deliverables for the first funding period (4 years) and, in case of extension, the expected outcomes of the 8-year funding period.*
	1. Overview of the planned research design (general overview of plans for 8 years, a more detailed overview for the first 4 years) (max. 2000 characters)
* *Explain which aspects of the proposed research project are especially innovative.*
* *Describe the scientific and clinical relevance and potential impact of the proposed work and the topicality of the research.*
	1. Scientific methods, study design and research design (including work packages/sub-projects) and feasibility (max. 2000 characters)
* *Specify the methodology you intend to use to answer your research questions and to reach the objectives.*
* *Describe the basic working principles and concepts and why the chosen approach/specific mix of approaches is the most suitable for the addressed research question.*
* *A clear description of the patient cohort and solid statistical evaluation should be included.*
* *Please indicate if there are published articles on the patient cohorts. Include a description of any publicly available data that will be used.*
* *Clearly describe the working plan for the first funding period (4 years) and, in case of extension, the expected outcomes of the 8-year funding period.*
	1. Expected results, clinical relevance/impact and novelty (level of innovation)

Table 7: Work packages/sub-projects and their expected results

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **No.** | **Work package/ sub-project title** | **Work Package/ Sub-Project Leader** | **m/f** | **Duration (months)** | **Start MM/YY** | **End MM/YY** | **Planned results** |
| 1 |  |  |  |  |  |  |  |
| 2 |  |  |  |  |  |  |  |
| n |  |  |  |  |  |  |  |

* 1. Schedule/research project overview

Figure 1: Gantt chart of the research project

*<INSERT GANTT CHART>*



* 1. Interdisciplinary collaborative aspects, role of team members/researchers (max. 1500 characters)
* *Which different disciplines are working together within the CRG and which partnerships across departments and/or institutions will result out of this CRG?*
* *Which collaborative elements are essential for the CRG to succeed; what makes the team more powerful than the sum of the individual contributions?*
* *A team member’s contribution should be integrated into the overall plan and should not appear merely as a resource.*
* *Each team member should describe their role in accomplishing the goal of the CRG. Describe at least the role of the planned CRG leads (1/3 of all Heads (including the Head, the Deputy Head(s), and the Work Package/Sub-Project Leader(s)) have to be female).*
* *Include further gender aspects.*
	1. Measures to advance research careers and description of the role of the Mentor (max. 1500 characters)
* *Detail what measures are planned to integrate and promote promising early career researchers within the CRG (e.g. training programmes, special measures, etc.).*
* *Are there clinician-scientist programmes or opportunities for research clinicians to be released from patient-care obligations (through temporary substitute programmes)?*
* *What are the plans concerning the role of the Mentor?*
	1. Potential ethical aspects (max. 700 characters)
* *If required, information should be given with respect to the ethical approval.*
* *Please provide information with respect to ethical approvals. Is ethical approval available covering the research project and prospective use of data and the planned analysis? If not, please describe the steps and timeline to receive ethical approval.*

Financial plan

*(Please multiply/delete rows for Cooperation Partners as needed)*

Table 8: Financial plan of Funding Period 1

| Institution | Type of cost | Year 1 | Year 2 | Year 3 | Year 4 | Total EUR |
| --- | --- | --- | --- | --- | --- | --- |
| Lead Institution | Personnel costs |   |   |   |   |   |
| Non-personnel costs |   |  |   |  |   |
| Overheads |  |  |   |  |   |
| Third party costs |  |  |  |  |  |
| In-kind contributions |   |   |   |   |   |
| Cooperation Partner 1 | Personnel costs |   |   |   |   |   |
| Non-personnel costs |   |  |   |  |   |
| Overheads |   |  |   |  |   |
| Third party costs |  |  |  |  |  |
| In-kind contributions |   |   |   |   |   |
| Cooperation Partner n | Personnel costs |   |   |   |   |   |
| Non-personnel costs |   |  |   |  |   |
| Overheads |   |  |   |  |   |
| Third party costs |  |  |  |  |  |
| In-kind contributions |   |   |   |   |   |

Authorisation and Affirmation

*(Please multiply/delete rows for Cooperation Partners and Work Package/Sub-Project Leaders as needed)*

Table 9: Authorisation and affirmation of institutions and key personnel

| **Institution/Role** | **Name of signing person** | **Date, signature, and stamp** |
| --- | --- | --- |
| **Lead Institution** |  |  |
| **Cooperation Partner 1** |  |  |
| **Cooperation Partner n** |  |  |
| **Mentor** |  |  |
| **Head** |  |  |
| **Work Package/Sub-Project Leader 1 (Deputy Head)** |  |  |
| **Work Package/Sub-Project Leader n** |  |  |

Attachments

* Please use the provided template to attach the CVs of the Mentor and Head as well as of Work Package/Sub-Project Leader(s).
* Brief ethical declaration.
* Please include other relevant attachments (e.g. letters of intent (each max. one page)).
1. 4-digit code as defined in: [Statistik Austria. Erhebung über Forschung und Experimentelle Entwicklung 2021. Österreichische Systematik der Wissenschaftszweige 2012; 2021](https://www.statistik.at/fileadmin/pages/1185/FE21-B2-WZ.pdf). (English translation of disciplines available from page 5 of the PDF file). [↑](#footnote-ref-1)